title: [Sneddon-Wilkinson disease: efficacy of intermittent adalimumab therapy after lost response to infliximab and etanercept].
abstract: BACKGROUND
  Sneddon-Wilkinson disease (SWD) is a rare chronic neutrophilic dermatosis. The first-line treatment is dapsone but resistance to treatment may sometimes pose a challenge.
  
  
  METHODS
  We report a multidrug-resistant patient who responded dramatically before gradually losing response to infliximab and then etanercept. Complete remission was again obtained with adalimumab.
  
  
  CONCLUSIONS
  Our case confirms the previously reported dramatic efficacy of anti-TNF biological agents in recalcitrant SWD but highlights the possibility of subsequent loss of response. Furthermore, it illustrates the efficacy of adalimumab in this indication.
authors: Service de médecine interne, université de Nice-Sophia Antipolis, hôpital Archet-1, CHU de Nice, 151, route de Saint-Antoine-de-Ginestière, 06202 Nice cedex 3, France. Electronic address: mathildemarie.v@gmail.com.
authors: M
authors: M
authors: Versini
authors: F
authors: F
authors: Mantoux
authors: K
authors: K
authors: Angeli
authors: T
authors: T
authors: Passeron
authors: J-P
authors: JP
authors: Lacour
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004351:Drug Resistance; D057915:Drug Substitution; D000068800:Etanercept; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications; D020556:Neutrophil Infiltration; D011701:PUVA Therapy; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012872:Skin Diseases, Vesiculobullous / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Adalimumab; Anti-TNF; Biothérapie anti-TNFalpha; Dermatose neutrophilique; Maladie de Sneddon-Wilkinson; Neutrophilic dermatosis; Sneddon-Wilkinson disease